Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
» FDA Grants Priority Review for Pfizer’s Glasdegib in Acute Myeloid Leukemia
FDA Grants Priority Review for Pfizer’s Glasdegib in Acute Myeloid Leukemia
FDA Grants Priority Review for Pfizer’s Glasdegib in Acute Myeloid Leukemia
Submitted by
CP Staff
on June 27, 2018 - 9:57am
Source:
CP Wire
News Tags:
Pfizer
glasdegib
acute myeloid leukemia
Headline:
FDA Grants Priority Review for Pfizer’s Glasdegib in Acute Myeloid Leukemia
snippet:
Glasdegib combined with chemotherapy almost doubled overall survival compared to chemotherapy alone
PDUFA goal date is set in December of 2018
Ph III trials began enrolling patients earlier this year
